Phase I Clinical Study to Evaluate the Safety and Efficacy of RGB-5088 in Patients With Type 1 Diabetes Mellitus

NCT06731218 PHASE1 RECRUITING

This Phase I clinical trial is a single-center, single-arm, open-label study aimed at evaluating the safety and therapeutic efficacy of RGB-5088 islet cell transplantation in patients with Type 1 Diabetes Mellitus.

Details

Lead sponsor	Hangzhou Reprogenix Bioscience, Inc
Phase	PHASE1
Status	RECRUITING
Enrolment	10
Start date	Mon Feb 17 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Wed Dec 31 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Diabetes Mellitus, Type 1
• Diabetes Mellitus

Interventions

• RGB-5088

Countries

China